41:I[185,["/_next/static/chunks/0sxns9k8ywops.js","/_next/static/chunks/11fk-1ie3w6mp.js","/_next/static/chunks/1uc4qdk4uj22c.js","/_next/static/chunks/0jvahffpql9nd.js","/_next/static/chunks/0agcep-t686m_.js","/_next/static/chunks/2_mrasy1s2owt.js","/_next/static/chunks/1nsk8jrr9fqe6.js"],"SendEmailButton"] 43:I[63625,["/_next/static/chunks/0sxns9k8ywops.js","/_next/static/chunks/11fk-1ie3w6mp.js","/_next/static/chunks/1uc4qdk4uj22c.js","/_next/static/chunks/0jvahffpql9nd.js","/_next/static/chunks/0agcep-t686m_.js","/_next/static/chunks/2_mrasy1s2owt.js","/_next/static/chunks/1nsk8jrr9fqe6.js"],"AddToLibraryButton"] 44:I[29721,["/_next/static/chunks/0sxns9k8ywops.js","/_next/static/chunks/11fk-1ie3w6mp.js","/_next/static/chunks/1uc4qdk4uj22c.js","/_next/static/chunks/0jvahffpql9nd.js","/_next/static/chunks/0agcep-t686m_.js","/_next/static/chunks/2_mrasy1s2owt.js","/_next/static/chunks/1nsk8jrr9fqe6.js"],"ShareButton"] 45:I[58016,["/_next/static/chunks/0sxns9k8ywops.js","/_next/static/chunks/11fk-1ie3w6mp.js","/_next/static/chunks/1uc4qdk4uj22c.js","/_next/static/chunks/0jvahffpql9nd.js","/_next/static/chunks/0agcep-t686m_.js","/_next/static/chunks/2_mrasy1s2owt.js","/_next/static/chunks/1nsk8jrr9fqe6.js"],"ProcessEpisodeButton"] 46:I[45269,["/_next/static/chunks/0sxns9k8ywops.js","/_next/static/chunks/11fk-1ie3w6mp.js","/_next/static/chunks/1uc4qdk4uj22c.js","/_next/static/chunks/0jvahffpql9nd.js","/_next/static/chunks/0agcep-t686m_.js","/_next/static/chunks/2_mrasy1s2owt.js","/_next/static/chunks/1nsk8jrr9fqe6.js"],"SignupCTA"] 3a:["$","h1",null,{"className":"max-w-[22ch] font-display text-[clamp(32px,4.5vw,48px)] font-medium leading-[1.05] tracking-[-0.02em] text-[color:var(--fg-1)] text-balance","children":"Why GLP-1s Could Be Biggest Brug Breakthrough Ever"}] 3b:["$","div",null,{"className":"flex flex-wrap items-center gap-x-4 gap-y-1 font-mono text-[12px] uppercase tracking-[0.1em] text-[color:var(--fg-3)]","children":[["$","time",null,{"dateTime":"2026-06-24T16:06:00.000Z","children":"June 24, 2026"}],["$","span",null,{"aria-hidden":true,"children":"·"}],["$","span",null,{"children":"00:30:02"}],false]}] 42:T516,

For centuries, the dream of effortless weight loss has been chased through fad diets and herbal decoctions, but a modern cultural transformation is finally rewriting the rules.

In this episode, we go inside the phenomenon of GLP-1 receptor agonists that are moving beyond social media buzz to reshape entire industries.

We explore the science of how these medications mimic the glucagon-like peptide-1 hormone to regulate appetite and insulin, transforming obesity from a perceived personal failure into a treatable medical condition.

The impact stretches far beyond the pharmacy counter. We examine the "ripple effect" on the global economy: from gym cultures pivoting to strength training to combat "Ozempic butt," to the "food industry tremors" as giants like Nestlé and Walmart adapt to a world of shrinking appetites.

Discover the startling "weight reduction" math for airlines, where even a 10-pound drop per passenger could save millions in annual fuel costs.

As we look toward a future of dual and triple agonists, we ask the ultimate question: are we witnessing a simple weight-loss trend, or a medical breakthrough that could change the treatment of over 175 different conditions?